{
  "id": 2063829,
  "title": "Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock",
  "url": "https://urgent.news/2026/08/20/camp4-therapeutics-cso-daniel-tardiff-sells-8-272-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-20T03:30:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/camp4-therapeutics-cso-daniel-tardiff-sells-8272-in-common-stock-93CH-4868654"
  },
  "original_language": "en",
  "account": "Chief Scientific Officer Daniel Tardiff of Camp4 Therapeutics sold 1,738 shares of the company's common stock on August 19, 2026, for a total of $8,272. The shares were sold at $4.76 each and were purchased through the company's Employee Stock Purchase Plan from January 1, 2026, to June 30, 2026. Despite Camp4 shares delivering a 202% return over the past year, the stock is currently near its InvestingPro Fair Value estimate. The company boasts a strong balance sheet, with more cash than debt and liquid assets exceeding short-term obligations. Investors can find additional valuation metrics and 7 ProTips on the InvestingPro platform. Recently, CAMP4 Therapeutics received attention from analysts, including JPMorgan upgrading its stock rating from Neutral to Overweight and increasing its price target to $9.00. Chardan also initiated coverage on the company with a buy rating and a price target of $6.50, highlighting optimism about the clinical-stage biotechnology company's prospects.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Yahoo Finance",
        "title": "Red Robin Stock Is in the Middle of a Tasty Turnaround You Don’t Want to Miss",
        "url": "https://urgent.news/2026/08/18/red-robin-stock-is-in-the-middle-of-a-tasty-turnaround-you-dont-want",
        "published": "2026-08-18T15:45:02.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "An2 Therapeutics director Robin Readnour sells $212,701 in common stock",
        "url": "https://urgent.news/2026/08/19/an2-therapeutics-director-robin-readnour-sells-212-701-in-common-stock",
        "published": "2026-08-19T22:30:57.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}